Pat is Head of the Biotechnology and Life Sciences Group, one of the biggest Groups of its type in Europe.
Pat has a life sciences and pharmaceuticals practice for clients based in the United States, the UK, the rest of Europe and Japan. He has directed prosecution of patent families covering over 70 countries, but a high proportion of Pat's work is prosecution, opposition and appeal work in the European Patent Office (EPO). He has handled about 60 opposition matters in the EPO over the course of his career to date. He has advised on multi-national litigation and counsels clients on freedom-to-operate issues.
Examples of subjects that Pat has patented for clients include the following: vaccines including whooping cough vaccines that are given to babies across Europe and the United States; antibodies including an antibody for treating osteoporosis, romosozumab, that is being developed by two global biopharmaceutical companies and is in phase 3 clinical trials; biologicals including pegylated G-CSF, a product used to treat patients suffering from low levels of white blood cells as a result of cancer chemotherapy; small molecule drugs including enzalutamide, the world's top-selling drug for prostate cancer; techniques for converting non-pluripotent cells into pluripotent cells; methods of engineering bacteria to produce chemicals for making polymers; drought-resistant plants invented at a US university; and diagnostic tests for heart disease and cancer.
Pat was a scholar at Cambridge University and graduated from there in 1991 with a first class degree in Natural Sciences and specialisms in biochemistry and organic chemistry. He qualified as a European patent attorney in 1995 and as a UK chartered patent attorney in 1996. During his professional exams, he was awarded the prize for the top mark in the UK in the Patent Attorneys' Practice Paper.
He became a partner in 2001, served on the firm's Management Committee from 2009 to 2013, and stepped down from the Management Committee in 2013 to take on the role of Head of Biotechnology and Life Sciences. He has overseen the firm's graduate recruitment programme since early 2014.
Pat is ranked in "Band 1" by Chambers & Partners and is recommended by The Legal 500 and the Managing Intellectual Property (MIP) Handbook. According to a client quoted in the 2017 edition of Chambers & Partners, Pat "is forward-thinking and has done a phenomenal job on EPO oppositions".
University of Cambridge, Masters Degree in Natural Sciences
Member of the Institute of Professional Representatives before the European Patent Office (EPI), European Patent Attorney, UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA)